Who
Andrew Sinclair
Director
Company insider
Files Form 4 as: Director, Adicet Bio; Director, Soleno Therapeutics; Director, Sierra Oncology; Director, Verona Pharma.
In numbers
- Trades disclosed
- 85
- Buys
- 7
- Sells
- 0
- Bought
- $33.8M
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 21 Dec 2018
- Last trade
- 21 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 18 May 2026filed 18 May 2026 | Soleno TherapeuticsBiotechnology | SEC FORM 4 Code D | —10,491 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,333 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —823 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,333 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —823 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —635 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,124 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —635 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,124 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,666 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeutics | SEC FORM 4 Code D | —10,491 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,000 | filing |
News
No headline names them, or the companies they trade most, lately.